How might Viagra impact cardiac health?

How might Viagra impact cardiac health?

There isn't much data to support the theory that taking Viagra can lead to cardiovascular issues. However, those who use nitrates, a drug that addresses cardiovascular diseases, may experience extremely low blood pressure when using Viagra.

In the United States, 52% of males between the ages of 40 and 70 suffer from erectile dysfunction. Viagra, also known as sildenafil, is a well-liked medication for this illness. 

This article examines the potential cardiac effects of using Viagra. It first gives a summary of the facts before examining the advantages and possible hazards of taking Viagra for the heart.

In the US, cardiovascular illness is a major cause of death: heart disease accounts for about 1 in 4Trusted Source fatalities.

A review of earlier research published in 2021 states that there have been worries after reports that Viagra may raise a patient's risk of experiencing life-threatening arrhythmias or other heart-related problems. 

The authors point out that this might not apply to people with healthy hearts, though. The use of Viagra has not been linked by researchers to an increased risk of cardiovascular disease. There may even be some heart-related benefits to using Viagra. 

Are there any hazards associated with the heart when taking Viagra?

Using Viagra does not appear to raise the risk of a heart attack, as the 2021 review indicates. 

Nonetheless, persons with high blood pressure may experience negative effects from using Viagra, particularly if they also use blood pressure-lowering drugs. This is as a result of Viagra's ability to reduce blood pressure. 

Physicians advise against using Viagra in patients on nitrates since it can result in dangerously low blood pressure. 

Does using Viagra have any benefits for the heart?

Viagra might be beneficial to a person's cardiovascular health. Medics refer to these outcomes as cardioprotective. 

Some animal research indicate that Viagra may lower the risk of heart disease, as noted in the same 2021 review. Not every study, though, supports this conclusion. There needs to be more research, including human research. 

There is some evidence that Viagra can help treat pulmonary artery hypertension due to its tendency to reduce blood pressure Trusted Source. The arteries in the lungs and the right side of the heart are impacted by this type of hypertension.

                                                         

To whom not to prescribe Viagra?

It is advised by researchers that Viagra use be avoided by those who take nitrates. One treatment for high blood pressure is nitrates. Nitrates are also used by doctors to treat angina. A type of chest pain called angina is brought on by a decrease in blood flow to the heart muscles. 

If a person's blood pressure is low, they shouldn't use Viagra. Those who suffer from the following ailments also experience this:

A obstruction in the blood arteries that convey blood from the lungs to the heart is known as pulmonary veno-occlusion. 

Low blood flow from the left ventricles of the heart is known as left ventricular outflow blockage. 

A disorder called sickle cell anemia affects the red blood cells. 

Multiple system atrophy is a disorder that damages the nerve cells in the brain.

Substitutes for Viagra Several drugs have been created by scientists to treat erectile dysfunction.

These drugs include vardenafil (Levitra or Staxyn), according to the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. avanafil (Stendra) tadalafil (Cialis) A few lifestyle changes may also be beneficial for erectile dysfunction. These include cutting back on alcohol consumption, frequent exercise, and giving up smoking.


To Know more download:https://www.cardiology.scientexconference.com/brochure

 

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more